The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
125732041 12573204 1 I 20160711 20160720 20160720 EXP JP-ROCHE-1792782 ROCHE KATO T, MORISE M, ANDO M, KOJIMA E, OGASAWARA T, SUZUKI R, SHINDOH J, MATSUMOTO M, SUGINO Y, OGAWA M, NOZAKI Y, HASE T, KONDO M, SAITO H AND HASEGAWA Y. CAN WE PREDICT THE DEVELOPMENT OF SERIOUS ADVERSE EVENTS (SAES) AND EARLY TREATMENT TERMINATION IN ELDERLY NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS RECEIVING PLATINUM BASED CHEMOTHERAPY?. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2016 JUL 01;142 (7):1629-1640. 0.00 E Y 0.00000 20160720 OT JP JP

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
125732041 12573204 1 PS Bevacizumab BEVACIZUMAB 1 Unknown U 125085 SOLUTION FOR INFUSION
125732041 12573204 2 SS CARBOPLATIN. CARBOPLATIN 1 Unknown U 0
125732041 12573204 3 SS PEMETREXED PEMETREXED 1 Unknown U 0
125732041 12573204 4 SS CISPLATIN. CISPLATIN 1 Unknown U 0
125732041 12573204 5 SS PACLITAXEL. PACLITAXEL 1 Unknown U 0
125732041 12573204 6 SS GEMCITABINE GEMCITABINEGEMCITABINE HYDROCHLORIDE 1 Unknown U 0
125732041 12573204 7 SS DOCETAXEL. DOCETAXEL 1 Unknown U 0
125732041 12573204 8 SS VINORELBINE VINORELBINEVINORELBINE TARTRATE 1 Unknown U 0
125732041 12573204 9 SS IRINOTECAN IRINOTECAN 1 Unknown U 0
125732041 12573204 10 SS ETOPOSIDE. ETOPOSIDE 1 Unknown U 0
125732041 12573204 11 SS TS-1 GIMERACILOTERACILTEGAFUR 1 Unknown U 0

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
125732041 12573204 1 Non-small cell lung cancer
125732041 12573204 2 Non-small cell lung cancer
125732041 12573204 3 Non-small cell lung cancer
125732041 12573204 4 Non-small cell lung cancer
125732041 12573204 5 Non-small cell lung cancer
125732041 12573204 6 Non-small cell lung cancer
125732041 12573204 7 Non-small cell lung cancer
125732041 12573204 8 Non-small cell lung cancer
125732041 12573204 9 Non-small cell lung cancer
125732041 12573204 10 Non-small cell lung cancer
125732041 12573204 11 Non-small cell lung cancer

Outcome of event

Event ID CASEID OUTC COD
125732041 12573204 OT
125732041 12573204 DE

Reactions reported

Event ID CASEID DRUG REC ACT PT
125732041 12573204 Alanine aminotransferase increased
125732041 12573204 Anaemia
125732041 12573204 Aspartate aminotransferase increased
125732041 12573204 Blood bilirubin increased
125732041 12573204 Blood creatine increased
125732041 12573204 Cerebrovascular accident
125732041 12573204 Decreased appetite
125732041 12573204 Febrile neutropenia
125732041 12573204 Infection
125732041 12573204 Lung infection
125732041 12573204 Nausea
125732041 12573204 Neuropathy peripheral
125732041 12573204 Neutropenia
125732041 12573204 Peripheral sensory neuropathy
125732041 12573204 Pleural infection
125732041 12573204 Pneumonitis
125732041 12573204 Pulmonary haemorrhage
125732041 12573204 Thrombocytopenia
125732041 12573204 Vomiting

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

no results found